Abstract
Currently, the evaluation of in vivo antimicrobial efficacy predominantly relies on endpoint detection methods, such as Colony Forming Units (CFU) counting and histopathological staining following animal sacrifice, to assess the antimicrobial properties of materials. These traditional detection methods struggle to capture real-time changes in infection status during treatment. This study proposes a novel strategy utilizing lipophilic near-infrared dye (e.g., DIR, [1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide]) for bacterial fluorescent labeling, combined with In Vivo Imaging System (IVIS) technology, to achieve real-time monitoring of dynamic changes in bacterial infection in localized infection models. Following local injection of stained bacteria, IVIS imaging revealed temporal changes in fluorescence signals within infected areas, which were further utilized to evaluate the in vivo efficacy of antimicrobial biomaterials. We have effectively validated this approach in a rat bone defect infection model. Additionally, this method can be used in conjunction with micro-CT to enable three-dimensional observation. Experimental results demonstrate that this approach intuitively reflects the immediate effects of antimicrobial treatment and facilitates precise quantitative analysis, providing technical support for in vivo detection of antimicrobial efficacy.
Impact Statement
This study introduces a groundbreaking method for real-time monitoring of antimicrobial biomaterial efficacy using lipophilic near-infrared dye (DIR) bacterial labeling combined with IVIS technology. Unlike traditional endpoint detection methods that require animal sacrifice, this noninvasive approach enables continuous observation of infection dynamics within the same subject, significantly reducing animal usage while improving data continuity. Successfully validated in a rat bone defect model and compatible with micro-CT for 3D visualization, this innovation provides researchers with a powerful tool for antimicrobial biomaterial development, infectious disease modeling, and antibiotic drug screening.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
